Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: -106.00 (-0.87%)
Spread: 2.00 (0.017%)
Open: 12,092.00
High: 12,178.00
Low: 12,010.00
Prev. Close: 12,156.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET OPEN: TUI Slides After Profit Warning, AstraZeneca Falls

Fri, 29th Mar 2019 08:48

LONDON (Alliance News) - Stocks in London opened in the green on Friday, ahead another key day for the UK's future with the EU, with the FTSE 100 higher despite declines by TUI and AstraZeneca. The FTSE 100 index was up 47.02 points higher, or 0.7%, at 7,281.35.The FTSE 250 was up 116.83 points, or 0.7%, at 19,025.42, while the AIM All-Share index was up 0.3% at 913.93.The Cboe UK 100 index was up 0.7% at 12,357.87. The Cboe UK 250 was up 0.4% at 17,039.56, though the Cboe UK Small Companies was 0.1% lower at 11,142.32.In mainland Europe, the CAC 40 in Paris and the DAX 30 in Frankfurt were up 1.0% and 0.6% respectively in early trade.In the FTSE 100, German holiday firm TUI slumped 9.7% after it guided for a EUR200 million earnings before interest, tax, and amortisation hit due to the grounding of Boeing's 737 MAX planes.TUI said the impact is due to costs of replacing the aircraft, increased fuel spend, and "other costs" related to the grounding. As a result, TUI expects underlying Ebita for its financial year ending September to fall 17%, changed from guidance previously of it being flat on EUR1.18 billion the year before.Further, if the situation regarding the aircraft - involved in two recent fatal crashes - is not resolved by the summer, Ebita could fall as much as 26% year-on-year. AstraZeneca slipped 3.6% as it plans a USD3.5 billion equity placing as part of a USD6.9 billion collaboration with Daiichi Sankyo.The global development and commercialisation agreement covers the potential cancer treatment trastuzumab deruxtecan.Under the agreement, Astra will make an upfront USD1.35 billion payment to Daiichi Sankyo, half due on execution and half 12 months later, followed by contingent payments of as much as USD5.55 billion for a total of up to USD6.9 billion.Of the USD5.55 billion, USD3.80 billion will be paid out to the Japanese company for regulatory milestones and USD1.75 billion will be for sales-related milestones.The upfront USD1.35 billion payment and near-term milestones are to be covered by a new equity placing to raise approximately USD3.5 billion - more than half of which will be used to fund the transaction and ongoing collaboration.Miners were higher early on, with BHP Group rising 1.8%, Glencore 2.2%, Antofagasta 2.2%, Rio Tinto 2.3% and Anglo American 2.0%. FTSE 250-listed Ferrexpo, an iron ore pellet maker, rose 4.0%, amid a report from Reuters that Rio Tinto has declared force majeure on some of its contract due to damage caused by cyclone Veronica in Australia. A rising iron ore price has helped Ferrexpo shares gain 30% over the past three months, driven by the Brumadinho dam disaster in Brazil in January. Investment manager MAN Group was 3.8% higher, as Credit Suisse initiated it with an Outperform rating. Elsewhere, waste-to-energy firm Renewi slumped 15% as it warned earnings before interest and tax at its ATM hazardous waste treatment plant will fall by around EUR25 million for its year ending March 2020, as it is assuming no shipments will be made.Overall, trading in its year ending Sunday has been in line, with the Dutch Commercial Division doing well in particular. Integration activity is on track to deliver savings of EUR30 million for the year.Renewi has extended its bank covenants to June 2020, one year on from before, and will be paying a 0.5p final dividend, giving a total of 1.45p, lower from 2.1p year-on-year.Life insurer Chesnara was down 1.1%, as it upped its annual dividend despite a big profit fall, paying a final dividend of 13.46 pence. This takes its 2018 total to 20.67p, 3% higher year-on-year.Pretax profit dropped to GBP27.0 million from GBP89.6 million, after a one-off gains the year prior, while comprehensive income has declined to GBP23.7 million from GBP86.9 million, again due to one-off gains the prior year as well as swing to a foreign exchange loss.Cash generation was strong, Chesnara said, at GBP47.8 million, up from GBP28.6 million.Its solvency ratio was 158%, from 146% year-on-year, showing the firm is "well capitalised".Chesnara's outlook is positive, it said, with the UK business in particular doing well.Veterinary group CVS reported 24% growth in revenue to GBP195.1 million for the six months to December, but pretax profit slumped 74% to GBP1.6 million. Like-for-like revenue rose 4.0%.The stock was 14% higher in early trade.On an adjusted basis, pretax profit fell to GBP17.4 million from GBP18.3 million. Profit has been hurt by a steep rise in administrative expenses.CVS said the result was "disappointing", and the effort going forward will be to ensure organic revenue growth, improve the gross margin, and review costs.US and Chinese trade teams on Friday resumed negotiations in Beijing to end months-long trade frictions.Chinese Vice Premier Liu He welcomed US Trade Representative Robert Lighthizer and Treasury Secretary Steven Mnuchin at a government guesthouse in Beijing for the second and last day of talks.Liu is scheduled to travel to Washington next week, as the top officials continue negotiations over issues such as intellectual property protection, the amount of imports, forced technology transfers and government subsidies.The two teams will "spare no effort" in carrying negotiations meant to end a months-long trade war, Chinese Commerce Ministry spokesman Gao Feng said Thursday.Market sentiment has also been boosted by a report by Reuters saying the two countries have made "unprecedented" progress on the thorny issue of technology transfer.In the US on Thursday, Wall Street ended higher, with the Dow Jones Industrial Average closing up 0.4%, the S&P 500 also up 0.4%, and the Nasdaq Composite ending up 0.3%.The Japanese Nikkei 225 index closed up 0.8%. In China, the Shanghai Composite ended up 3.2%, while the Hang Seng index in Hong Kong is up 1.0%.UK Prime Minister Theresa May is battling to get her Brexit Withdrawal Agreement backed by the Commons on the day that was scheduled to see Britain quit the EU.The prime minister split the legally binding treaty segment of her Brexit deal from the declaration on future relations with the EU in order to ensure MPs could vote on it on Friday.But May faced an uphill struggle as key government allies the DUP joined Labour leader Jeremy Corbyn in saying they would vote against the move.The PM's decision to present just the Withdrawal Agreement to the Commons means it is not a third attempt to pass a "meaningful vote" on the government's Brexit deal and complies with rules laid down by Commons Speaker John Bercow.UK consumer confidence remained negative in March, a monthly survey showed on Friday, though fears over the general economy persist.The GfK UK Consumer Confidence Index reading for March was minus 13, the same as February's score. A year ago, however, the reading had been minus 7."Against a backdrop of stable inflation and a robust labour market, where wages continue to grow more quickly than prices, confidence has remained negative but fairly stable since the referendum," said Joe Staton, client strategy director at GfK, a market research company."However, while UK consumers report a small increase in optimism for their personal financial situation for the coming year, the index is being dragged down by our nagging fears for the general economy," he noted."Things might change when people feel the current crisis has passed but what sort of resolution can consumers reasonably contemplate just now? Or are consumers rightly sensing a bumpier economic climate for post-Brexit Britain?"The economic events calendar on Friday has German unemployment at 0855 GMT and UK fourth-quarter GDP data at 0930 GMT.In the afternoon there is US personal spending data at 1230 GMT, including the core personal consumption expenditure index reading - the Fed's preferred inflation measure.

More News
2 Jan 2024 11:00

Weight-loss drugs: Who, and what, are they good for?

Jan 2 (Reuters) - Powerful weight-loss medicines like Novo Nordisk's Wegovy leapt into public view in 2023, from social media to doctors' offices and cocktail parties, offering a new way to address record obesity rates.

Read more
2 Jan 2024 11:00

What other health conditions might weight-loss drugs treat?

Jan 2 (Reuters) - Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss therapy Wegovy are being studied to see whether they can improve health in other ways.

Read more
2 Jan 2024 08:48

LONDON MARKET OPEN: New Year begins largely green amid slew of PMIs

(Alliance News) - Stock prices in London opened mostly up on Tuesday, the first day of trading in 2024, reacting to slightly improved factory activity in China, with more manufacturing PMIs from major economies due.

Read more
2 Jan 2024 08:26

AstraZeneca and Sanofi received approval in China for RSV antibody

(Alliance News) - AstraZeneca PLC and Sanofi SA's long-acting monoclonal antibody Beyfortus received approval for use in China to prevent respiratory syncytial virus disease, Astra said on Tuesday.

Read more
2 Jan 2024 07:57

LONDON BRIEFING: AstraZeneca, Sanofi's RSV treatment approved in China

(Alliance News) - Stock prices in London are expected to open higher on Tuesday, reacting to a slight expansion in manufacturing activity in China and ahead of a slew of manufacturing PMI data including for the UK.

Read more
27 Dec 2023 17:04

Rate-cut optimism, autos push UK stocks higher

FTSE 100 up 0.4%, FTSE 250 adds 0.5%

*

Read more
27 Dec 2023 17:02

LONDON MARKET CLOSE: Stocks start week higher as 2024 draws to close

(Alliance News) - Equities in London kicked off an abbreviated trading week with gains on Wednesday, on continued US interest rate optimism at the end of 2024.

Read more
27 Dec 2023 14:25

London close: Stocks maintain gains amid post-Christmas rally

(Sharecast News) - London's stock markets closed in positive territory on Wednesday, buoyed by a global surge in stock prices as the S&P 500 neared an all-time high on Wall Street.

Read more
27 Dec 2023 12:06

LONDON MARKET MIDDAY: Stocks hold onto gains amid US rate cut hopes

(Alliance News) - London's FTSE 100 index was outperforming other European stock-price measures at midday on Wednesday, boosted by gains for miners and industrials.

Read more
27 Dec 2023 11:20

London midday: Stocks ride global wave of post-Christmas optimism

(Sharecast News) - London's equity markets were still above the waterline at lunchtime on Wednesday, following a late Santa rally on Wall Street overnight.

Read more
27 Dec 2023 08:48

LONDON MARKET OPEN: FTSE 100 gains led by miners and industrials

(Alliance News) - Stock prices in London opened in the green on Wednesday, as hopes for US interest rate cuts in the new year continued to propel global equities higher.

Read more
27 Dec 2023 08:26

London open: FTSE takes cues from Wall Street 'Santa rally'

(Sharecast News) - London's stocks returned from the Christmas break in the green on Wednesday, boosted by a late Santa rally on Wall Street overnight.

Read more
27 Dec 2023 08:24

TOP NEWS: AstraZeneca buys Gracell to "enrich" cell therapy pipeline

(Alliance News) - AstraZeneca PLC on Tuesday said it has agreed to acquire Gracell Biotechnologies Inc, paying about USD1.2 billion for the clinical-stage company.

Read more
27 Dec 2023 07:52

LONDON BRIEFING: AstraZeneca buys Gracell Biotech; COPL CEO resigns

(Alliance News) - Stocks in London were expected to make gains at Wednesday's market open, as investors continued to pin their hopes on US interest rate cuts.

Read more
27 Dec 2023 07:02

AstraZeneca to buy Gracell Technologies for $1.2bn

(Sharecast News) - AstraZeneca on Wednesday said it was buying Gracell Biotechnologies, a global clinical-stage biopharmaceutical company developing cell therapies for the treatment of cancer and autoimmune diseases, for $1.2bn.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.